{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T23:06:20Z","timestamp":1740179180655,"version":"3.37.3"},"reference-count":24,"publisher":"Georg Thieme Verlag KG","issue":"01","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TH Open"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Background\u2003Patients with atrial fibrillation (AF) and chronic kidney disease (CKD) are at high risk for both thromboembolism and bleeding events. The latter induces a potential reason for withholding oral anticoagulation (OAC) despite an indication for prophylaxis of thromboembolic events.<\/jats:p><jats:p>\n          Methods\u2003AF patients with CKD (estimated glomerular filtration [eGFR] rate between 15 and 49\u2009mL\/min per 1.73\u2009m2) were included in a prospective international registry in Europe between 2016 and 2020, that is, XARENO (factor XA inhibition in renal patients with nonvalvular atrial fibrillation observational registry). The study enrolled adult patients treated at the discretion of physicians with rivaroxaban, vitamin K antagonists (VKA), or without OAC (w\/oOAC). Here, we report a prespecified explorative baseline comparison between patients receiving OAC or no OAC within XARENO.<\/jats:p><jats:p>\n          Results\u2003In total, 1,544 patients (mean age: 78.2 years, mean eGFR: 36.2\u2009mL\/min) were studied (rivaroxaban n\u2009=\u2009764, VKA n\u2009=\u2009691, w\/oOAC n\u2009=\u200989). Patients in the w\/oOAC group were older and had a similar stroke (mean CHA2DS2-VASc score 4.0) but higher bleeding risk (mean modified Hypertension, Abnormal Renal\/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs\/Alcohol Concomitantly score 2.5 vs. 1.8) compared with the OAC groups. The distribution of comorbidities including hypertension, diabetes, and heart failure was similar. Treatment with antiplatelet drugs was fivefold more frequent in the w\/oOAC group.<\/jats:p><jats:p>\n          Conclusion\u2003Only 5.8% of the overall population of AF patients with advanced CKD received no OAC. These patients were older and had a higher bleeding risk, which might explain this decision, but which contrasts with the more frequent use of antiplatelet drugs in this vulnerable group of patients.<\/jats:p>","DOI":"10.1055\/s-0044-1780529","type":"journal-article","created":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T00:12:38Z","timestamp":1708733558000},"page":"e106-e113","source":"Crossref","is-referenced-by-count":1,"title":["Risk Profiles and Treatment Patterns in Atrial Fibrillation Patients with Chronic Kidney Disease Receiving or not Receiving Anticoagulation Therapy"],"prefix":"10.1055","volume":"08","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4818-211X","authenticated-orcid":false,"given":"Reinhold","family":"Kreutz","sequence":"additional","affiliation":[{"name":"Institute of Clinical Pharmacology and Toxicology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilbert","family":"Deray","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Paris 6 University, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Floege","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Clinical Immunology, RWTH Aachen University Hospital, Aachen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Gwechenberger","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Hahn","sequence":"additional","affiliation":[{"name":"Nephrologische Praxis, Dortmund, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas R.","family":"Luft","sequence":"additional","affiliation":[{"name":"Center for Neurology and Rehabilitation, Klinik f\u00fcr Neurologie, Universit\u00e4tsspital Z\u00fcrich, Switzerland and Cereneo, Vitznau, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pontus","family":"Persson","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Vegetative Physiologie, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Axthelm","sequence":"additional","affiliation":[{"name":"Cardiologicum Pirna and Dresden, Dresden, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juerg Hans","family":"Beer","sequence":"additional","affiliation":[{"name":"Department Innere Medizin, Baden Switzerland and Center of Molecular Cardiology, Kantonsspital Baden, University of Z\u00fcrich, Z\u00fcrich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jutta","family":"Bergler-Klein","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Lellouche","sequence":"additional","affiliation":[{"name":"Service de Cardiologie 1, Centre Hospitalier Universitaire Henri Mondor, Cr\u00e9teil, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Taggeselle","sequence":"additional","affiliation":[{"name":"Praxis Dr. med. Jens Taggeselle, Markkleeberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Beyer-Westendorf","sequence":"additional","affiliation":[{"name":"Thrombosis Research Unit, Division Haematology, Department of Medicine I, University Hospital Carl Gustav Carus Dresden, Dresden, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"issue":"05","key":"ref1","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrneph.2018.19","article-title":"Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction","volume":"14","author":"T S Potpara","year":"2018","journal-title":"Nat Rev Nephrol"},{"issue":"17","key":"ref2","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/j.jacc.2019.08.1031","article-title":"Anticoagulation in concomitant chronic kidney disease and atrial fibrillation: JACC review topic of the week","volume":"74","author":"S Kumar","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"9921","key":"ref3","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"C T Ruff","year":"2014","journal-title":"Lancet"},{"issue":"05","key":"ref4","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"G Hindricks","year":"2021","journal-title":"Eur Heart J"},{"issue":"10","key":"ref5","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"M R Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"19","key":"ref6","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/eurheartj\/ehr342","article-title":"Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment","volume":"32","author":"K A Fox","year":"2011","journal-title":"Eur Heart J"},{"issue":"23","key":"ref7","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.jacc.2014.09.051","article-title":"Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study","volume":"64","author":"A N Bonde","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"06","key":"ref8","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/ckj\/sfac022","article-title":"Efficacy and safety of warfarin in patients with non-valvular atrial fibrillation and CKD G3-G5D","volume":"15","author":"F Welander","year":"2022","journal-title":"Clin Kidney J"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12959-019-0211-y","article-title":"Non-vitamin K antagonist oral anticoagulants vs. vitamin-K antagonists in patients with atrial fibrillation and chronic kidney disease: a nationwide cohort study","volume":"17","author":"E K Laugesen","year":"2019","journal-title":"Thromb J"},{"issue":"23","key":"ref11","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/j.jacc.2015.03.577","article-title":"Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY trial","volume":"65","author":"M B\u00f6hm","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"ref12","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1016\/j.jacc.2017.09.1087","article-title":"Renal outcomes in anticoagulated patients with atrial fibrillation","volume":"70","author":"X Yao","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"ref13","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.33963\/KP.a2021.0134","article-title":"Rationale and design of XARENO: XA inhibition in RENal patients with non-valvular atrial fibrillation. Observational registry","volume":"79","author":"R Kreutz","year":"2021","journal-title":"Kardiol Pol"},{"issue":"09","key":"ref14","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"A S Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"04","key":"ref15","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"S Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"12","key":"ref16","doi-asserted-by":"crossref","first-page":"e017157","DOI":"10.1136\/bmjopen-2017-017157","article-title":"Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation","volume":"7","author":"K AA Fox","year":"2017","journal-title":"BMJ Open"},{"issue":"02","key":"ref17","first-page":"5","article-title":"Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation","volume":"5","author":"X Yao","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"06","key":"ref18","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.kint.2020.02.010","article-title":"Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference","volume":"97","author":"A S Levey","year":"2020","journal-title":"Kidney Int"},{"issue":"12","key":"ref19","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1111\/ggi.13531","article-title":"Atrial fibrillation and medication treatment among centenarians: are all very old patients treated the same?","volume":"18","author":"R Kreutz","year":"2018","journal-title":"Geriatr Gerontol Int"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejim.2021.01.020","article-title":"Long-term effectiveness and safety of anticoagulation therapy in oldest old, frail people with atrial fibrillation","volume":"86","author":"V Calsolaro","year":"2021","journal-title":"Eur J Intern Med"},{"issue":"03","key":"ref21","doi-asserted-by":"crossref","first-page":"e010510","DOI":"10.1161\/JAHA.118.010510","article-title":"Management and 1-year outcomes of patients with newly diagnosed atrial fibrillation and chronic kidney disease: results from the prospective GARFIELD\u2014AF Registry","volume":"8","author":"S Goto","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"07","key":"ref22","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/JAHA.117.005657","article-title":"Thromboembolic risk, bleeding outcomes and effect of different antithrombotic strategies in very elderly patients with atrial fibrillation: a sub-analysis from the PREFER in AF (PREvention oF Thromboembolic Events-European Registry in Atrial Fibrillation)","volume":"6","author":"G Patti","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"05","key":"ref23","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"R Pisters","year":"2010","journal-title":"Chest"},{"issue":"18","key":"ref24","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJMoa2012883","article-title":"Low-dose edoxaban in very elderly patients with atrial fibrillation","volume":"383","author":"K Okumura","year":"2020","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"991293","DOI":"10.3389\/fcvm.2022.991293","article-title":"Net clinical benefit of antithrombotic therapy for atrial fibrillation patients with stable coronary artery disease","volume":"9","author":"S R Lee","year":"2022","journal-title":"Front Cardiovasc Med"}],"container-title":["TH Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0044-1780529.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T13:12:39Z","timestamp":1730812359000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0044-1780529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":24,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2024,1,8]]},"published-print":{"date-parts":[[2024,1]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0044-1780529","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2512-9465"],"issn-type":[{"type":"electronic","value":"2512-9465"}],"subject":[],"published":{"date-parts":[[2024,1]]}}}